These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 8777179)

  • 21. Combination chemotherapy using carboplatin (JM-8) and etoposide (JET therapy) for recurrent malignant gliomas: a phase II study.
    Watanabe K; Kanaya H; Fujiyama Y; Kim P
    Acta Neurochir (Wien); 2002 Dec; 144(12):1265-70; discussion 1270. PubMed ID: 12478337
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma.
    Chamberlain MC; Wei-Tsao DD; Blumenthal DT; Glantz MJ
    Cancer; 2008 May; 112(9):2038-45. PubMed ID: 18361434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
    J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study.
    Yung WK; Prados M; Levin VA; Fetell MR; Bennett J; Mahaley MS; Salcman M; Etcubanas E
    J Clin Oncol; 1991 Nov; 9(11):1945-9. PubMed ID: 1658242
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
    Sipos L; Vitanovics D; Afra D
    Ideggyogy Sz; 2004 Nov; 57(11-12):394-9. PubMed ID: 15662767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KRN8602 (MX2-hydrochloride): an active new agent for the treatment of recurrent high-grade glioma.
    Clarke K; Basser RL; Underhill C; Mitchell P; Bartlett J; Cher L; Findlay M; Dalley D; Pell M; Byrne M; Geldard H; Hill JS; Maher D; Fox RM; Green MD; Kaye AH
    J Clin Oncol; 1999 Aug; 17(8):2579-84. PubMed ID: 10561325
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen.
    Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Raphael B; Vinci RZ
    J Clin Oncol; 1994 Mar; 12(3):553-9. PubMed ID: 8120553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II study of paclitaxel in chemonaïve patients with recurrent high-grade glioma.
    Postma TJ; Heimans JJ; Luykx SA; van Groeningen CJ; Beenen LF; Hoekstra OS; Taphoorn MJ; Zonnenberg BA; Klein M; Vermorken JB
    Ann Oncol; 2000 Apr; 11(4):409-13. PubMed ID: 10847458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Topotecan for the treatment of recurrent or progressive central nervous system tumors - a pediatric oncology group phase II study.
    Kadota RP; Stewart CF; Horn M; Kuttesch JF; Burger PC; Kepner JL; Kun LE; Friedman HS; Heideman RL
    J Neurooncol; 1999 May; 43(1):43-7. PubMed ID: 10448870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The New Approaches to Brain Tumor Therapy.
    Grossman SA; Hochberg F; Fisher J; Chen TL; Kim L; Gregory R; Grochow LB; Piantadosi S
    Cancer Chemother Pharmacol; 1998; 42(2):118-26. PubMed ID: 9654111
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II trial of topotecan in malignant melanoma.
    Kraut EH; Walker MJ; Staubus A; Gochnour D; Balcerzak SP
    Cancer Invest; 1997; 15(4):318-20. PubMed ID: 9246152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
    Rowinsky EK; Grochow LB; Hendricks CB; Ettinger DS; Forastiere AA; Hurowitz LA; McGuire WP; Sartorius SE; Lubejko BG; Kaufmann SH
    J Clin Oncol; 1992 Apr; 10(4):647-56. PubMed ID: 1312588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.
    Schiller JH; Kim K; Hutson P; DeVore R; Glick J; Stewart J; Johnson D
    J Clin Oncol; 1996 Aug; 14(8):2345-52. PubMed ID: 8708727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.
    Quinn JA; Reardon DA; Friedman AH; Rich JN; Sampson JH; Vredenburgh J; Gururangan S; Provenzale JM; Walker A; Schweitzer H; Bigner DD; Tourt-Uhlig S; Herndon JE; Affronti ML; Jackson S; Allen D; Ziegler K; Bohlin C; Lentz C; Friedman HS
    Neuro Oncol; 2004 Apr; 6(2):145-53. PubMed ID: 15134629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study.
    Hurwitz CA; Strauss LC; Kepner J; Kretschmar C; Harris MB; Friedman H; Kun L; Kadota R
    J Pediatr Hematol Oncol; 2001; 23(5):277-81. PubMed ID: 11464982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II study of topotecan in patients with recurrent head and neck cancer. Identification of an active new agent.
    Robert F; Soong SJ; Wheeler RH
    Am J Clin Oncol; 1997 Jun; 20(3):298-302. PubMed ID: 9167758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group Trial 9507.
    Fisher BJ; Scott C; Macdonald DR; Coughlin C; Curran WJ
    J Clin Oncol; 2001 Feb; 19(4):1111-7. PubMed ID: 11181676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.
    Ardizzoni A; Hansen H; Dombernowsky P; Gamucci T; Kaplan S; Postmus P; Giaccone G; Schaefer B; Wanders J; Verweij J
    J Clin Oncol; 1997 May; 15(5):2090-6. PubMed ID: 9164222
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pre-irradiation semi-intensive chemotherapy with carboplatin and cyclophosphamide in malignant glioma: a phase II study.
    Viñolas N; Gil M; Verger E; Villá S; Pujol T; Ceral L; García M; Graus F
    Anticancer Drugs; 2002 Feb; 13(2):163-7. PubMed ID: 11901309
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma.
    Gruber ML; Buster WP
    Am J Clin Oncol; 2004 Feb; 27(1):33-8. PubMed ID: 14758131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.